Matthias Ruebner
Overview
Explore the profile of Matthias Ruebner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
85
Citations
2508
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lehle S, Volkl S, Seitz K, Goossens C, Emons J, Ruebner M, et al.
BMC Immunol
. 2025 Mar;
26(1):21.
PMID: 40089714
Background: Peripheral blood mononuclear cells (PBMCs) are valuable biomarkers, providing crucial insights into the patients' immune system. Reliable biobanking of PBMCs is essential to minimize heterogeneity. In multicenter trials, blood...
2.
Hoppe R, Winter S, Lo W, Michailidou K, Bolla M, Keeman R, et al.
NPJ Breast Cancer
. 2025 Feb;
11(1):18.
PMID: 39971965
The role of germline genetics in adjuvant aromatase inhibitor (AI) treatment efficacy in ER-positive breast cancer is poorly understood. We employed a two-stage candidate gene approach to examine associations between...
3.
Huebner H, Wimberger P, Laakmann E, Ruckhaberle E, Ruebner M, Lehle S, et al.
Precis Clin Med
. 2025 Jan;
8(1):pbae034.
PMID: 39839709
Background: Circulating cell-free tumor DNA (ctDNA) provides a non-invasive approach for assessing somatic alterations. The German PRAEGNANT registry study aims to explore molecular biomarkers and investigate their integration into clinical...
4.
Eisenblatter R, Seifert F, Schurmann P, Beckhaus T, Hanel P, Jentschke M, et al.
HLA
. 2024 Aug;
104(2):e15597.
PMID: 39101335
Cervical cancer is the fourth most common cancer in females. Genome-wide association studies (GWASs) have proposed cervical cancer susceptibility variants at the HLA locus on chromosome 6p21. To corroborate these...
5.
Fasching P, Hack C, Nabieva N, Maass N, Aktas B, Kummel S, et al.
Eur J Cancer
. 2024 Jul;
209:114239.
PMID: 39059184
Background: The monarchE and NATALEE trials demonstrated the benefit of CDK4/6 inhibitor (CDK4/6i) therapy in adjuvant breast cancer (BC) treatment. Patient selection, based on clinical characteristics, delineated those at high...
6.
Fasching P, Hu C, Hart S, Ruebner M, Polley E, Gnanaolivu R, et al.
NPJ Breast Cancer
. 2024 Jul;
10(1):57.
PMID: 39003306
Germline mutations in BRCA1 and BRCA2 (gBRCA1/2) are required for a PARP inhibitor therapy in patients with HER2-negative (HER2-) advanced breast cancer (aBC). However, little is known about the prognostic...
7.
Saner F, Takahashi K, Budden T, Pandey A, Ariyaratne D, Zwimpfer T, et al.
Clin Cancer Res
. 2024 Jun;
30(16):3481-3498.
PMID: 38837893
Purpose: The purpose of this study was to evaluate RB1 expression and survival across ovarian carcinoma histotypes and how co-occurrence of BRCA1 or BRCA2 (BRCA) alterations and RB1 loss influences...
8.
Wunderle M, Heindl F, Behrens A, Haberle L, Hack C, Heusinger K, et al.
Arch Gynecol Obstet
. 2024 Jun;
310(2):1223-1233.
PMID: 38836929
Purpose: The receptor activator of nuclear factor kappa B (RANK) and its ligand (RANKL) have been shown to promote proliferation of the breast and breast carcinogenesis. The objective of this...
9.
Schneeweiss A, Brucker S, Huebner H, Volmer L, Hack C, Seitz K, et al.
Geburtshilfe Frauenheilkd
. 2024 May;
84(5):443-458.
PMID: 38817598
In recent years, new targeted therapies have been developed to treat patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Some of these therapies have not...
10.
Hack C, Maass N, Aktas B, Kummel S, Thomssen C, Wolf C, et al.
Geburtshilfe Frauenheilkd
. 2024 May;
84(2):e10.
PMID: 38690326
[This corrects the article DOI: 10.1055/a-2238-3153.].